cerevel therapeutics is a biopharmaceutical company focused on developing new therapies to treat disorders of the central nervous system (cns). the company has a portfolio of experimental neuroscience therapies, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of cns disorders, including parkinson’s, alzheimer’s, epilepsy, schizophrenia and addiction. headquartered in the greater boston area, cerevel was formed in 2018 through a partnership between bain capital and pfizer.
Company profile
Ticker
CERE
Exchange
Website
CEO
Anthony Coles Jr.
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ARYA Sciences Acquisition Corp II
SEC CIK
CERE stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
27 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
16 Feb 24
DEFA14A
Additional proxy soliciting materials
9 Feb 24
DEFM14A
Proxy related to merger
18 Jan 24
PRER14A
Preliminary revised proxy
18 Jan 24
PREM14A
Preliminary proxy related to merger
5 Jan 24
DEFA14A
Additional proxy soliciting materials
7 Dec 23
8-K
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
7 Dec 23
10-Q
2023 Q3
Quarterly report
1 Nov 23
8-K
Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
1 Nov 23
Transcripts
CERE
Earnings call transcript
2023 Q3
1 Nov 23
CERE
Earnings call transcript
2023 Q2
2 Aug 23
CERE
Earnings call transcript
2023 Q1
3 May 23
CERE
Earnings call transcript
2022 Q4
22 Feb 23
CERE
Earnings call transcript
2022 Q3
13 Nov 22
CERE
Earnings call transcript
2022 Q2
1 Aug 22
CERE
Earnings call transcript
2022 Q1
14 May 22
CERE
Earnings call transcript
2021 Q4
1 Mar 22
CERE
Earnings call transcript
2021 Q3
10 Nov 21
CERE
Earnings call transcript
2021 Q2
11 Aug 21
Latest ownership filings
4
N ANTHONY COLES
3 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
N ANTHONY COLES
6 Mar 24
4
N ANTHONY COLES
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
29 Feb 24
4
JOSEPH EDELMAN
21 Feb 24
5
Gabrielle Sulzberger
13 Feb 24
4
John Renger
8 Feb 24
4
N ANTHONY COLES
8 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 157.68 mm | 157.68 mm | 157.68 mm | 157.68 mm | 157.68 mm | 157.68 mm |
Cash burn (monthly) | 6.68 mm | 7.73 mm | 37.10 mm | 35.18 mm | 24.21 mm | 27.70 mm |
Cash used (since last report) | 44.63 mm | 51.66 mm | 247.88 mm | 235.05 mm | 161.75 mm | 185.04 mm |
Cash remaining | 113.05 mm | 106.02 mm | -90.20 mm | -77.37 mm | -4.07 mm | -27.36 mm |
Runway (months of cash) | 16.9 | 13.7 | -2.4 | -2.2 | -0.2 | -1.0 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 122 |
Opened positions | 25 |
Closed positions | 32 |
Increased positions | 53 |
Reduced positions | 25 |
13F shares | Current |
---|---|
Total value | 3.01 tn |
Total shares | 228.11 mm |
Total puts | 439.97 k |
Total calls | 268.60 k |
Total put/call ratio | 1.6 |
Largest owners | Shares | Value |
---|---|---|
BC Perception | 60.63 mm | $1.94 bn |
Bain Capital Investors | 60.20 mm | $1.31 tn |
PFE Pfizer | 27.35 mm | $957.50 mm |
FMR | 23.62 mm | $515.69 bn |
Perceptive Advisors | 10.09 mm | $220.23 bn |
Vanguard | 6.37 mm | $139.09 bn |
T. Rowe Price | 5.50 mm | $119.97 bn |
BLK Blackrock | 4.99 mm | $108.95 bn |
STT State Street | 2.90 mm | $63.31 bn |
Paradigm Biocapital Advisors | 2.53 mm | $55.29 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Coles N Anthony | Common Stock | Sell | Dispose S | No | Yes | 42.3328 | 50,000 | 2.12 mm | 15,638 |
1 Apr 24 | Coles N Anthony | Common Stock | Option exercise | Acquire M | No | Yes | 3.5 | 50,000 | 175.00 k | 65,638 |
1 Apr 24 | Coles N Anthony | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 3.5 | 50,000 | 175.00 k | 2,302,417 |
29 Feb 24 | Coles N Anthony | Common Stock | Sell | Dispose S | No | Yes | 41.1578 | 50,000 | 2.06 mm | 15,638 |
29 Feb 24 | Coles N Anthony | Common Stock | Option exercise | Acquire M | No | Yes | 3.5 | 50,000 | 175.00 k | 65,638 |
29 Feb 24 | Coles N Anthony | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 3.5 | 50,000 | 175.00 k | 2,402,417 |
7 Feb 24 | John Renger | Common Stock | Sell | Dispose S | No | No | 41.5441 | 2,161 | 89.78 k | 6,370 |
7 Feb 24 | Coles N Anthony | Common Stock | Sell | Dispose S | No | No | 41.5441 | 2,506 | 104.11 k | 15,638 |
6 Feb 24 | John Renger | Common Stock | Option exercise | Acquire M | No | No | 0 | 5,020 | 0.00 | 8,531 |
6 Feb 24 | John Renger | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 5,020 | 0.00 | 15,061 |
News
Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study
18 Apr 24
Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday?
25 Mar 24
Mizuho Maintains Neutral on Cerevel Therapeutics Hldg, Raises Price Target to $45
16 Feb 24
This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space
16 Feb 24
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst
6 Feb 24
Press releases
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease
18 Apr 24
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates MGRC, SNCE, VINE, CERE
29 Jan 24
CEREVEL THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cerevel Therapeutics - CERE
26 Jan 24
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates WAVD, CERE, TGAN
24 Jan 24
Kuehn Law Encourages MDC, WAVD, NS and CERE Investors to Contact Law Firm
24 Jan 24